ManmeetSinghAhluwaliaMD

Hematologic Oncology, Neuro-Oncology

Fernandez Family Foundation Endowed Chair in Cancer Research | Chief of Medical Oncology | Chief Scientific Officer & Deputy Director | Miami Cancer Institute, Baptist Health South Florida

Request Appointment

Overview of Dr. Ahluwalia

Dr. Manmeet Ahluwalia is an oncologist in Miami, FL and is affiliated with Baptist Hospital of Miami. He received his medical degree from Maulana Azad Medical College and has been in practice 17 years. Dr. Ahluwalia accepts several types of health insurance, listed below. He is one of 58 doctors at Baptist Hospital of Miami who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
8900 N Kendall Dr
Miami, FL 33176
Book by Phone+1(786) 952-5058

Fax+1 305-279-7778

Education & Training

University at BuffaloFellowship, Hematology and Medical Oncology, 2008 - 2009
University at BuffaloFellowship, Hematology and Medical Oncology, 2006 - 2007
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 2003 - 2006
Maulana Azad Medical CollegeClass of 2000

Certifications & Licensure

TX State Medical License 2009 - Present
FL State Medical License 2020 - 2025
OH State Medical License 2003 - 2025

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014-2022
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013

Clinical Trials

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma Start of enrollment: 2012 Dec 20
Completed
Phase 2
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma Start of enrollment: 2013 Jun 12
Completed
Phase 2
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin Lymphoma Start of enrollment: 2014 Mar 01
Terminated
Phase 2
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Start of enrollment: 2015 May 04
Active, not recruiting
Phase 2
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM Start of enrollment: 2018 May 21
Active, not recruiting
Phase 2
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma Start of enrollment: 2019 Jul 31
Active, not recruiting
Phase 2
Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue Start of enrollment: 2024 Jun 01
Not yet recruiting
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Immune checkpoint inhibitors for glioblastoma: emerging science, clinical advances, and future directions.
Aarav Badani, Ahmad Ozair, Mustafa Khasraw, Graeme F Woodworth, Pallavi Tiwari
Journal of Neuro-Oncology. 2025-02-01
Leptomeningeal metastatic disease: new frontiers and future directions.
Ahmad Ozair, Hannah Wilding, Debarati Bhanja, Nicholas Mikolajewicz, Michael Glantz
Nature Reviews. Clinical Oncology. 2025-02-01
Phase I study of adavosertib with radiation therapy and temozolomide in newly diagnosed glioblastoma and intratumoral drug levels in recurrent glioblastoma.
Eudocia Q Lee, Brian M Alexander, Carlos G Romo, Jeffrey G Supko, Nathalie Y R Agar
Clinical Cancer Research. 2025-01-17

Journal Articles

Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched ...
Cosette Dechant, Gene H Barnett, Andreas Seas, Eric C Leuthardt, Kevin O Juarez, Hanna Kemeny, Peter E Fecci, Manmeet S Ahluwalia, Mayur Sharma, Thomas L Beaumont, Alb..., Neurosurgery
Expression of LC3B and FIP200/Atg17 in Brain Metastases of Breast Cancer
Manmeet S Ahluwalia, Lingling Du, Adam Lauko, Robert J Weil, Samuel T Chao, Journal of Neuro-Oncology
Chapter 11 - Systemic Therapy for Brain Metastases
Manmeet Ahluwalia, MD, ScienceDirect

Lectures

SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.
2019 ASCO Annual Meeting - 6/1/2019
Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
14th Annual Brain Tumor Update AND 3rd Annual International Symposium on Long-Term Control of Metastases to the Brain and Spine
Cleveland Clinic - Cleveland, Ohio / The Cleveland Clinic Foundation, Las Vegas, Nevada - 9/22/2012
Join now to see all

Authored Content

First-in-Human Evaluation of the Cleveland Multiport Catheter for Convection-Enhanced Delivery of Topotecan in Recurrent High-Grade Glioma: Results of Pilot Trial 1 RelatedApril 2018
First-in-Human Evaluation of the Cleveland Multiport Catheter for Convection-Enhanced Delivery of Topotecan in Recurrent High-Grade Glioma: Results of Pilot Trial 1 RelatedApril 2018

Press Mentions

Advances in Managing Brain Metastases in RCCJanuary 7th, 2025
Precision Oncology Summit to Feature Novel Therapies, Latest Cancer Treatment AdvancesJanuary 1st, 2025
HealthNovember 25th, 2024
Join now to see all

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
HealthAmerica HealthAssurance PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment